NeoLAB™ EGFR T790M Liquid Biopsy
Accurate and sensitive detection of the EGFR T790M mutation using cell-free plasma DNA
NeoLAB™ EGFR T790M, A Non-invasive Liquid Biopsy Alternative to Aid in Patient Management
NeoLAB EGFR T790M – Liquid Biopsy testing is now being offered at NeoGenomics Laboratories to detect the T790M acquired resistance mutation with very high sensitivity (0.1%) using cell-free circulating tumor DNA. This new assay provides a powerful alternative for situations involving limited access to tissue samples.
NeoLAB EGFR T790M Benefits
- Reduces need for tissue sample and surgery
- Frequent testing and monitoring made possible with ability to analyze peripheral blood plasma
- High sensitivity (0.1%)
- Aids in therapy selection
- Improved accuracy using two methods for results confirmation
When to Order
For NSCLC patients that have developed an acquired resistance to prior TKI treatment and are suspected to have an EGFR T790M acquired resistance mutation. Helpful in situations where limited or no tissue is available for testing and for identifying patients that may respond to third generation EGFR TKIs.
|NeoLAB EGFR T790M|
Peripheral blood: 5 mL in EDTA tube